HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma

Blood

Volumn 122, Issue 8, 2013, Pages 1448-1454

  Alcoceba, Miguel ^a,b   Sebastián, Elena ^a,b,c   Marin, Luis ^a,b   Balanzategui, Ana ^a,b   Sarasquete, M Eugenia ^a,b   Chillón, M Carmen ^a,b   Jiménez, Cristina ^a,b   Puig, Noemi ^a,b   Corral, Rocio ^a,b   Pardal, Emilia ^c   Grande, Carlos ^c   Bello, Joé Luis ^c   Albo, Carmen ^c   Cruz, Fatimadela ^c   Panizo, Carlos ^c   Martin, Alejandro ^a,b,c   Gonzalez Barca, Eva ^c   Caballero, M Dolores ^a,b,c   San Miguel, Jesus F ^a,b,d   Garcia Sanz, Ramon ^a,b,d   González, Marcos ^a,b,d   more..

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA IBSAL   (Spain)

^c Spanish Lymphoma/Autologous Bone Marrow Transplant Study Group ^*  (Spain)

^d Centro de Investigacion del Cancer   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE PLUS DOXORUBICIN PLUS PREDNISOLONE PLUS RITUXIMAB PLUS VINCRISTINE; HLA A ANTIGEN; HLA B ANTIGEN; HLA B44 ANTIGEN; HLA C ANTIGEN; HLA DQB1 ANTIGEN; HLA DRB1 ANTIGEN; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; HLA ANTIGEN; MONOCLONAL ANTIBODY; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CARCINOGENESIS; CONTROLLED STUDY; DIFFUSE LARGE B CELL LYMPHOMA; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; HUMAN; INTERNATIONAL PROGNOSTIC INDEX; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POST TREATMENT SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; CASE CONTROL STUDY; DISEASE FREE SURVIVAL; GENETICS; LARGE CELL LYMPHOMA; MIDDLE AGED; PHENOTYPE; PROGNOSIS; RISK FACTOR; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CASE-CONTROL STUDIES; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; GENE FREQUENCY; HLA ANTIGENS; HLA-DRB1 CHAINS; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, GENETIC; PREDNISOLONE; PROGNOSIS; RISK FACTORS; VINCRISTINE; YOUNG ADULT;

EID: 84886997025     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-02-483420     Document Type: Article

References (49)

1. Rothman N, Skibola CF, Wang SS, et al. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: A report from the InterLymph Consortium. Lancet Oncol. 2006;7(1): 27-38.
2. Skibola CF, Bracci PM, Nieters A, et al. Tumor necrosis factor (TNF) and lymphotoxin-alpha (LTA) polymorphisms and risk of non-Hodgkin lymphoma in the InterLymph Consortium. Am J Epidemiol. 2010;171(3):267-276.
3. Skibola CF, Bracci PM, Halperin E, et al. Genetic variants at 6p21.33 are associated with susceptibility to follicular lymphoma. Nat Genet. 2009;41(8):873-875.
4. Conde L, Halperin E, Akers NK, et al. Genomewide association study of follicular lymphoma identifies a risk locus at 6p21.32. Nat Genet. 2010;42(8):661-664.
5. Smedby KE, Foo JN, Skibola CF, et al. GWAS of follicular lymphoma reveals allelic heterogeneity at 6p21.32 and suggests shared genetic susceptibility with diffuse large B-cell lymphoma. PLoS Genet. 2011;7(4): E1001378.
6. Cozen W, Li D, Best T, et al. A genome-wide meta-analysis of nodular sclerosing Hodgkin lymphoma identifies risk loci at 6p21.32. Blood. 2012;119(2):469-475.
7. Urayama KY, Jarrett RF, Hjalgrim H, et al. Genome-wide association study of classical Hodgkin lymphoma and Epstein-Barr virus statusdefined subgroups. J Natl Cancer Inst. 2012; 104(3):240-253.
8. Chaperot L, Delfau-Larue MH, Jacob MC, et al. Differentiation of antitumor-specific cytotoxic T lymphocytes from autologous tumor infiltrating lymphocytes in non-Hodgkin's lymphomas. Exp Hematol. 1999;27(7):1185-1193.
9. Montes-Ares O, Moya-Quiles MR, Montes- Casado M, et al. Human leucocyte antigen-C in B chronic lymphocytic leukaemia. Br J Haematol. 2006;135(4):517-519.
10. Alcoceba M, Marín L, Balanzategui A, et al. The presence of DRB1∗01 allele in multiple myeloma patients is associated with an indolent disease. Tissue Antigens. 2008;71(6):548-551.
11. Urayama KY, Chokkalingam AP, Metayer C, et al. HLA-DP genetic variation, proxies for early life immune modulation and childhood acute lymphoblastic leukemia risk. Blood. 2012;120(15): 3039-3047.
12. Nathalang O, Tatsumi N, Hino M, Prayoonwiwat W, Yamane T, Suwanasophon C, Sriphaisal T. HLA class II polymorphism in Thai patients with non-Hodgkin's lymphoma. Eur J Immunogenet. 1999;26(6):389-392.
13. Juszczynski P, Kalinka E, Bienvenu J, et al. Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome. Blood. 2002;100(8):3037-3040.
14. Nowak J, Kalinka-Warzocha E, Juszczyński P, et al. Haplotype-specific pattern of association of human major histocompatibility complex with non- Hodgkin's lymphoma outcome. Tissue Antigens. 2008;71(1):16-26.
15. Wang SS, Abdou AM, Morton LM, et al. Human leukocyte antigen class I and II alleles in non- Hodgkin lymphoma etiology. Blood. 2010; 115(23):4820-4823.
16. Lu Y, Abdou AM, Cerhan JR, et al. Human leukocyte antigen class I and II alleles and overall survival in diffuse large B-cell lymphoma and follicular lymphoma. ScientificWorldJournal. 2011; 11:2062-2070.
17. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008.
18. A clinical evaluation of the International Lymphoma Study Group classification of non- Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood. 1997; 89(11):3909-3918.
19. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275-282.
20. Gonzalez-Barca E, Salar A, Bargay J, et al. Efficacy of dose-dense R-CHOP-14 Chemoimmunotherapy plus pegfilgrastim for firstline treatment of diffuse large B-cell lymphoma (DLBCL) in low risk patients: An interim analysis of an open-label clinical trial in Spain. On behalf of GEL/TAMO (Spanish Group of Lymphoma) [abstract]. Blood. 2007;110(11):3443.
21. Arranz R, Conde E, Grande C, et al; Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea (GEL-TAMO). Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: A prospective study from the GEL-TAMO Study Group. Eur J Haematol. 2008;80(3):227-235.
22. Coronado M, Pardal E, Couto R, et al. Prognostic value of interim PET/CT in patients with poor risk diffuse large B-cell lymphoma (DLBCL): Experience of the Spanish GELTAMO Group [abstract]. Blood. 2012;120(21):5076.
23. Alcoceba M, Marín L, Balanzategui A, et al. Frequency of HLA-A, -B and -DRB1 specificities and haplotypic associations in the population of Castilla y León (northwest-central Spain). Tissue Antigens. 2011;78(4):249-255.
24. González M, González D, López-Pérez R, et al. Heteroduplex analysis of VDJ amplified segments from rearranged IgH genes for clonality assessments in B-cell non-Hodgkin's lymphoma. A comparison between different strategies. Haematologica. 1999;84(9):779-784.
25. Sidney J, Peters B, Frahm N, Brander C, Sette A. HLA class I supertypes: A revised and updated classification. BMC Immunol. 2008;9:1.
26. Greenbaum J, Sidney J, Chung J, Brander C, Peters B, Sette A. Functional classification of class II human leukocyte antigen (HLA) molecules reveals seven different supertypes and a surprising degree of repertoire sharing across supertypes. Immunogenetics. 2011;63(6): 325-335.
27. Excoffier L, Lischer HE. Arlequin suite ver 3.5: A new series of programs to perform population genetics analyses under Linux and Windows. Mol Ecol Resour. 2010;10(3):564-567.
28. Cheson BD, Pfistner B, Juweid ME, et al; International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5): 579-586.
29. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol. 2011;29:235-271.
30. Drénou B, Le Friec G, Bernard M, et al. Major histocompatibility complex abnormalities in non- Hodgkin lymphomas. Br J Haematol. 2002;119(2): 417-424.
31. Drénou B, Tilanus M, Semana G, et al. Loss of heterozygosity, a frequent but a non-exclusive mechanism responsible for HLA dysregulation in non-Hodgkin's lymphomas. Br J Haematol. 2004; 127(1):40-49.
32. Seliger B, Ritz U, Ferrone S. Molecular mechanisms of HLA class I antigen abnormalities following viral infection and transformation. Int J Cancer. 2006;118(1):129-138.
33. Borgerding A, Hasenkamp J, Engelke M, Burkhart N, Trümper L, Wienands J, Glass B. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression. Exp Hematol. 2010;38(3):213-221.
34. Wilkinson ST, Vanpatten KA, Fernandez DR, et al. Partial plasma cell differentiation as a mechanism of lost major histocompatibility complex class II expression in diffuse large B-cell lymphoma. Blood. 2012;119(6):1459-1467.
35. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate antitumor immunity. Curr Opin Immunol. 2012;24(2): 207-212.
36. Ghodke Y, Joshi K, Chopra A, Patwardhan B. HLA and disease. Eur J Epidemiol. 2005;20(6): 475-488.
37. Rioux JD, Goyette P, Vyse TJ, et al; International MHC and Autoimmunity Genetics Network. Mapping of multiple susceptibility variants within the MHC region for 7 immune-mediated diseases. Proc Natl Acad Sci USA. 2009;106(44): 18680-18685.
38. Holoshitz J. The rheumatoid arthritis HLA-DRB1 shared epitope. Curr Opin Rheumatol. 2010; 22(3):293-298.
39. Newman B, Silverberg MS, Gu X, et al. CARD15 and HLA DRB1 alleles influence susceptibility and disease localization in Crohn's disease. Am J Gastroenterol. 2004;99(2):306-315.
40. Ekström Smedby K, Vajdic CM, Falster M, et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: A pooled analysis within the InterLymph Consortium. Blood. 2008;111(8): 4029-4038.
41. Colonna M, Brooks EG, Falco M, Ferrara GB, Strominger JL. Generation of allospecific natural killer cells by stimulation across a polymorphism of HLA-C. Science. 1993;260(5111):1121-1124.
42. Yen JH, Moore BE, Nakajima T, et al. Major histocompatibility complex class I-recognizing receptors are disease risk genes in rheumatoid arthritis. J Exp Med. 2001;193(10):1159-1167.
43. Martin MP, Nelson G, Lee JH, et al. Cutting edge: Susceptibility to psoriatic arthritis: Influence of activating killer Ig-like receptor genes in the absence of specific HLA-C alleles. J Immunol. 2002;169(6):2818-2822.
44. Martin MP, Gao X, Lee JH, et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet. 2002;31(4): 429-434.
45. Khakoo SI, Thio CL, Martin MP, et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science. 2004;305(5685): 872-874.
46. Feugier P, Van Hoof A, Sebban C, et al. Longterm results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005; 23(18):4117-4126.
47. Merli F, Luminari S, Rossi G, et al; for the Fondazione Italiana Linfomi. Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by Comprehensive Geriatric Assessment: Results from a study of the Fondazione Italiana Linfomi [published online ahead of print April 30, 2013]. Leuk Lymphoma
48. Cortes J, Fayad L, Kantarjian H, O'Brien S, Lee MS, Talpaz M. Association of HLA phenotype and response to interferon-alpha in patients with chronic myelogenous leukemia. Leukemia. 1998; 12(4):455-462.
49. Cabrera T, Maleno I, Lopez-Nevot MA, et al. High frequency of HLA-B44 allelic losses in human solid tumors. Hum Immunol. 2003;64(10): 941-950.